AIM: To investigate the influence of infliximab (Remicade) on experimental colitis produced by 2,4,6,trinitrobenzene sulfonic acid (TNBS) in rats. METHODS: Thirty-six Wistar rats were allocated into four groups (three groups of six animals each and a fourth of 12 animals). Six more healthy animals served as normal controls (Group 5). Group 1: colitis was induced by intracolonic installation of 25 mg of TNBS dissolved in 0.25 mL of 50% ethanol and infliximab was subcutaneously administered at a dose of 5 mg/kg BW; Group 2: colitis was induced and infliximab was subcutaneously administered at a dose of 10 mg/kg BW; Group 3: colitis was induced and infliximab was subcutaneously administered at a dose of 15 mg/kg BW; Group 4: colitis was induced without treatment with infliximab. Infliximab was administered on d 2-6. On the 7(th) d, all animals were killed. The colon was fixed in 10% buffered formalin and examined by light microscopy for the presence and activity of colitis and the extent of tissue damage. Tumor necrosis factor-alpha (TNF-alpha) and malondialdehyde (MDA) were also measured. RESULTS: Significant differences concerning the presence of reparable lesions and the extent of bowel mucosa without active inflammation in all groups of animals treated with infliximab compared with controls were found. Significant reduction of the tissue levels of TNF-alpha in all groups of treated animals as compared with the untreated ones was found (0.47+/-0.44, 1.09+/-0.86, 0.43+/-0.31 vs 18.73+/-10.53 respectively). Significant reduction in the tissue levels of MDA was noticed in group 1 as compared to group 4, as well as between groups 2 and 4. CONCLUSION: Subcutaneous administration of infliximab reduces the inflammatory activity as well as tissue TNF-alpha and MDA levels in chemical colitis in rats. Infliximab at a dose of 5 mg/kg BW achieves better histological results and produces higher reduction of the levels of TNF-alpha than at a dose of 10 mg/kg BW. Infliximab at a dose of 5 mg/kg BW produces higher reduction of tissue MDA levels than at a dose of 15 mg/kg BW.
AIM: To investigate the influence of infliximab (Remicade) on experimental colitis produced by 2,4,6,trinitrobenzene sulfonic acid (TNBS) in rats. METHODS: Thirty-six Wistar rats were allocated into four groups (three groups of six animals each and a fourth of 12 animals). Six more healthy animals served as normal controls (Group 5). Group 1: colitis was induced by intracolonic installation of 25 mg of TNBS dissolved in 0.25 mL of 50% ethanol and infliximab was subcutaneously administered at a dose of 5 mg/kg BW; Group 2: colitis was induced and infliximab was subcutaneously administered at a dose of 10 mg/kg BW; Group 3: colitis was induced and infliximab was subcutaneously administered at a dose of 15 mg/kg BW; Group 4: colitis was induced without treatment with infliximab. Infliximab was administered on d 2-6. On the 7(th) d, all animals were killed. The colon was fixed in 10% buffered formalin and examined by light microscopy for the presence and activity of colitis and the extent of tissue damage. Tumor necrosis factor-alpha (TNF-alpha) and malondialdehyde (MDA) were also measured. RESULTS: Significant differences concerning the presence of reparable lesions and the extent of bowel mucosa without active inflammation in all groups of animals treated with infliximab compared with controls were found. Significant reduction of the tissue levels of TNF-alpha in all groups of treated animals as compared with the untreated ones was found (0.47+/-0.44, 1.09+/-0.86, 0.43+/-0.31 vs 18.73+/-10.53 respectively). Significant reduction in the tissue levels of MDA was noticed in group 1 as compared to group 4, as well as between groups 2 and 4. CONCLUSION: Subcutaneous administration of infliximab reduces the inflammatory activity as well as tissue TNF-alpha and MDA levels in chemical colitis in rats. Infliximab at a dose of 5 mg/kg BW achieves better histological results and produces higher reduction of the levels of TNF-alpha than at a dose of 10 mg/kg BW. Infliximab at a dose of 5 mg/kg BW produces higher reduction of tissue MDA levels than at a dose of 15 mg/kg BW.
Authors: Emiko Mizoguchi; Atsushi Mizoguchi; Hidetoshi Takedatsu; Elke Cario; Ype P de Jong; Choon Jin Ooi; Ramnik J Xavier; Cox Terhorst; Daniel K Podolsky; Atul K Bhan Journal: Gastroenterology Date: 2002-01 Impact factor: 22.682
Authors: S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245
Authors: D Jenkins; M Balsitis; S Gallivan; M F Dixon; H M Gilmour; N A Shepherd; A Theodossi; G T Williams Journal: J Clin Pathol Date: 1997-02 Impact factor: 3.411
Authors: Chinyu Su; Bruce A Salzberg; James D Lewis; Julius J Deren; Asher Kornbluth; David A Katzka; Robert B Stein; Douglas R Adler; Gary R Lichtenstein Journal: Am J Gastroenterol Date: 2002-10 Impact factor: 10.864
Authors: Kevin P Pavlick; F Stephen Laroux; John Fuseler; Robert E Wolf; Laura Gray; Jason Hoffman; Matthew B Grisham Journal: Free Radic Biol Med Date: 2002-08-01 Impact factor: 7.376
Authors: Carissa M Thomas; Delphine M A Saulnier; Jennifer K Spinler; Peera Hemarajata; Chunxu Gao; Sara E Jones; Ashley Grimm; Miriam A Balderas; Matthew D Burstein; Christina Morra; Daniel Roeth; Markus Kalkum; James Versalovic Journal: Microbiologyopen Date: 2016-06-28 Impact factor: 3.139
Authors: Ronaldo Parisi Buanaim; José Aires Pereira; Fabio Guilherme Campos; Paulo Gustavo Kotze; Eduardo Felipe Kim Goto; Roberta Laís Silva Mendonça; Danilo Toshio Kanno; Carlos Augusto Real Martinez Journal: Acta Cir Bras Date: 2019-12-13 Impact factor: 1.388
Authors: Apostolos E Papalois; Calypso Barbatis; Dimosthenis Chrysikos; Maria Korontzi; Michail Sideris; Theodoros Pittaras; Eleni Triantafyllidi; Alexandros Nomikos; John K Triantafillidis Journal: Biomed Res Int Date: 2019-10-09 Impact factor: 3.411
Authors: Shaymaa Ramzy Senousy; Mahmoud El-Daly; Ahmed R N Ibrahim; Mohamed Montaser A Khalifa; Al-Shaimaa F Ahmed Journal: Biomedicines Date: 2022-07-06
Authors: John K Triantafillidis; Georgia Douvi; George Agrogiannis; Efstratios Patsouris; Aristofanis Gikas; Apostolos E Papalois Journal: Biomed Res Int Date: 2014-05-04 Impact factor: 3.411